biotech

biotech Articles

Immunomedics shares dropped sharply on Monday after the firm presented interim data from its midstage bladder cancer study at the European Society for Medical Oncology (ESMO) Annual Congress in...
ImmunoGen shares dropped on Monday after the firm released data from its late-stage ovarian cancer study at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
Dova Pharmaceuticals shares jumped on Monday after the firm announced that it would be acquired by Swedish Orphan Biovitrum, or Sobi. But are Dova investors getting enough out of this acquisition?
Enanta Pharma shares dropped on Thursday after the company announced topline results from its Argon-1 Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH).
Achillion Pharma shares jumped on Wednesday after the firm announced that the FDA has granted Breakthrough Therapy designation for danicopan (ACH-4471).
PhaseBio Pharma shares jumped on Wednesday after the firm announced results from its midstage trial focused on novel therapies for cardiopulmonary orphan diseases.
The September 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
One analyst sees FDA approval of its noninvasive colorectal cancer screening test tacking on another 30% to Exact Sciences stock.
Viela Bio filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its IPO. The company intends to price 7.5 million shares in the range of $19 to $21, with an...
Acadia shares made a handy gain on Monday after the firm announced positive results from an eight-week Phase 2 study evaluating pimavanserin as a therapy for Parkinson’s disease patients with...
Avadel Pharma shares jumped on Monday morning after the firm announced that the FDA has agreed to the company’s proposed amendments to a statistical analysis plan and protocol.
Zynerba Pharmaceuticals has announced positive results from its midstage epilepsy trial, and yet its shares dropped on Wednesday.
NewLink Genetics shares jumped on Wednesday after the firm announced that the FDA has accepted Merck’s Biologics License Application and granted priority review for the investigational Ebola...
Karyopharm rose sharply on news of a royalty agreement that could bring as much as $150 million in new capital to the company, and one analyst sees much higher upside on the heels of the news.
Aimmune shares dipped on Monday after the FDA's Allergenic Products Advisory Committee voted to support the use of AR101 (Palforzia) in children and teens with peanut allergy.